Sarah Boyce - Net Worth and Insider Trading
Sarah Boyce Net Worth
The estimated net worth of Sarah Boyce is at least $6 Million dollars as of 2024-06-18. Sarah Boyce is the President and CEO of Avidity Biosciences Inc and owns about 112,117 shares of Avidity Biosciences Inc (RNA) stock worth over $4 Million. Sarah Boyce is the Director of OmniAb Inc and owns about 88,437 shares of OmniAb Inc (OABI) stock worth over $376,742. Sarah Boyce is also the Chief Business Officer of Ionis Pharmaceuticals Inc and owns about 8,931 shares of Ionis Pharmaceuticals Inc (IONS) stock worth over $364,028. Besides these, Sarah Boyce also holds Akcea Therapeutics Inc (AKCA) , PhenomeX Inc (CELL) . Details can be seen in Sarah Boyce's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sarah Boyce has not made any transactions after 2024-06-14 and currently still holds the listed stock(s).
Transaction Summary of Sarah Boyce
Sarah Boyce Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Sarah Boyce owns 7 companies in total, including PhenomeX Inc (CELL) , Avidity Biosciences Inc (RNA) , and Ligand Pharmaceuticals Inc (LGND) among others .
Click here to see the complete history of Sarah Boyce’s form 4 insider trades.
Insider Ownership Summary of Sarah Boyce
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CELL | PhenomeX Inc | 2021-03-01 | director |
RNA | Avidity Biosciences Inc | 2024-06-14 | director & President and CEO |
LGND | Ligand Pharmaceuticals Inc | 2019-10-15 | director |
2019-07-15 | director & President | ||
2018-01-16 | Chief Business Officer | ||
2022-11-01 | director | ||
2022-11-10 | director |
Sarah Boyce Latest Holdings Summary
Sarah Boyce currently owns a total of 5 stocks. Among these stocks, Sarah Boyce owns 112,117 shares of Avidity Biosciences Inc (RNA) as of June 14, 2024, with a value of $4 Million and a weighting of 80.11%. Sarah Boyce owns 88,437 shares of OmniAb Inc (OABI) as of November 10, 2022, with a value of $376,742 and a weighting of 6.8%. Sarah Boyce also owns 8,931 shares of Ionis Pharmaceuticals Inc (IONS) as of January 16, 2018, with a value of $364,028 and a weighting of 6.57%. The other 2 stocks Akcea Therapeutics Inc (AKCA) , PhenomeX Inc (CELL) have a combined weighting of 6.52% among all his current holdings.
Latest Holdings of Sarah Boyce
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
RNA | Avidity Biosciences Inc | 2024-06-14 | 112,117 | 39.60 | 4,439,833 |
OABI | OmniAb Inc | 2022-11-10 | 88,437 | 4.26 | 376,742 |
IONS | Ionis Pharmaceuticals Inc | 2018-01-16 | 8,931 | 40.76 | 364,028 |
AKCA | Akcea Therapeutics Inc | 2019-07-15 | 19,888 | 18.17 | 361,365 |
CELL | PhenomeX Inc | 2021-03-01 | 0 | 1.00 | 0 |
Holding Weightings of Sarah Boyce
Sarah Boyce Form 4 Trading Tracker
According to the SEC Form 4 filings, Sarah Boyce has made a total of 9 transactions in Avidity Biosciences Inc (RNA) over the past 5 years, including 0 buys and 9 sells. The most-recent trade in Avidity Biosciences Inc is the sale of 300,000 shares on June 14, 2024, which brought Sarah Boyce around $12 Million.
According to the SEC Form 4 filings, Sarah Boyce has made a total of 1 transactions in OmniAb Inc (OABI) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in OmniAb Inc is the acquisition of 36,000 shares on November 10, 2022, which cost Sarah Boyce around $101,520.
According to the SEC Form 4 filings, Sarah Boyce has made a total of 0 transactions in Ionis Pharmaceuticals Inc (IONS) over the past 5 years. The most-recent trade in Ionis Pharmaceuticals Inc is the sale of 2,196 shares on January 16, 2018, which brought Sarah Boyce around $113,665.
More details on Sarah Boyce's insider transactions can be found in the Insider Trading History of Sarah Boyce table.Insider Trading History of Sarah Boyce
- 1
Sarah Boyce Trading Performance
GuruFocus tracks the stock performance after each of Sarah Boyce's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Sarah Boyce is 28.31%. GuruFocus also compares Sarah Boyce's trading performance to market benchmark return within the same time period. The performance of stocks bought by Sarah Boyce within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Sarah Boyce's insider trading performs compared to the benchmark.
Performance of Sarah Boyce
Sarah Boyce Ownership Network
Ownership Network List of Sarah Boyce
Ownership Network Relation of Sarah Boyce
Sarah Boyce Owned Company Details
What does PhenomeX Inc do?
Who are the key executives at PhenomeX Inc?
Sarah Boyce is the director of PhenomeX Inc. Other key executives at PhenomeX Inc include Chief Financial Officer Mehul Joshi , director & Chief Executive Officer Siddhartha Kadia , and 10 percent owner Bird Mergersub Corp .
PhenomeX Inc (CELL) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of PhenomeX Inc (CELL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of PhenomeX Inc (CELL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
PhenomeX Inc (CELL)'s detailed insider trading history can be found in Insider Trading Tracker table.
PhenomeX Inc Insider Transactions
Sarah Boyce Mailing Address
Above is the net worth, insider trading, and ownership report for Sarah Boyce. You might contact Sarah Boyce via mailing address: C/o Ionis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad Ca 92010.